Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debulking Strategies Prior to Venetoclax in CLL
NCT03406156Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Achieving Low Tumor Burden Status With Induction at 24 weeks and Complete Remission Rate at Week 65. Started Aug 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03406156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406156.